{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T18:31:34Z","timestamp":1787596294634,"version":"build-2736575974"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100006407","name":"Natural Science Foundation of Henan Province","doi-asserted-by":"publisher","award":["242300420083"],"award-info":[{"award-number":["242300420083"]}],"id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017700","name":"Henan Provincial Science and Technology Research Project","doi-asserted-by":"publisher","award":["252102310434"],"award-info":[{"award-number":["252102310434"]}],"id":[{"id":"10.13039\/501100017700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s00109-026-02708-3","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T05:47:13Z","timestamp":1787550433000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The dual roles of lysine-specific demethylase 1 (KDM1A\/LSD1) in the modulation of tumor immune microenvironment and its inhibitors in colorectal cancer"],"prefix":"10.1007","volume":"104","author":[{"given":"Yuan-Ying","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Wei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Mei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8851-1953","authenticated-orcid":false,"given":"Zhi-Yu","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"issue":"5618","key":"2708_CR1","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1126\/science.1083558","volume":"300","author":"F Gaudet","year":"2003","unstructured":"Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J, Gray JW, Jaenisch R (2003) Induction of tumors in mice by genomic hypomethylation. Science 300(5618):489\u2013492. https:\/\/doi.org\/10.1126\/science.1083558","journal-title":"Science"},{"issue":"6","key":"2708_CR2","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1158\/0008-5472.CAN-08-3351","volume":"69","author":"HJ Jun","year":"2009","unstructured":"Jun HJ, Woolfenden S, Coven S, Lane K, Bronson R, Housman D, Charest A (2009) Epigenetic regulation of c-ROS receptor tyrosine kinase expression in malignant gliomas. Cancer Res 69(6):2180\u20132184. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-3351","journal-title":"Cancer Res"},{"issue":"6","key":"2708_CR3","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.molcel.2005.08.027","volume":"19","author":"YJ Shi","year":"2005","unstructured":"Shi YJ, Matson C, Lan F, Iwase S, Baba T, Shi Y (2005) Regulation of LSD1 histone demethylase activity by its associated factors. Mol Cell 19(6):857\u2013864. https:\/\/doi.org\/10.1016\/j.molcel.2005.08.027","journal-title":"Mol Cell"},{"issue":"7057","key":"2708_CR4","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature04020","volume":"437","author":"E Metzger","year":"2005","unstructured":"Metzger E, Wissmann M, Yin N, M\u00fcller JM, Schneider R, Peters AH, Sch\u00fcle R (2005) LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 437(7057):436\u2013439. https:\/\/doi.org\/10.1038\/nature04020","journal-title":"Nature"},{"issue":"7","key":"2708_CR5","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.cell.2004.12.012","volume":"119","author":"Y Shi","year":"2004","unstructured":"Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Shi Y (2004) Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119(7):941\u2013953. https:\/\/doi.org\/10.1016\/j.cell.2004.12.012","journal-title":"Cell"},{"issue":"26","key":"2708_CR6","doi-asserted-by":"publisher","first-page":"17775","DOI":"10.1074\/jbc.M109.003087","volume":"284","author":"A Karytinos","year":"2009","unstructured":"Karytinos A, Forneris F, Profumo A, Amati M, Tebaldi T, Binda C (2009) A novel mammalian flavin-dependent histone demethylase. J Biol Chem 284(26):17775\u201317782. https:\/\/doi.org\/10.1074\/jbc.M109.003087","journal-title":"J Biol Chem"},{"issue":"4","key":"2708_CR7","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.7150\/thno.66142","volume":"12","author":"W Zhang","year":"2022","unstructured":"Zhang W, Ruan X, Li Y, Wang F, Hu J, Wang B, Ji J (2022) KDM1A promotes thyroid cancer progression and maintains stemness through the Wnt\/\u03b2-catenin signaling pathway. Theranostics 12(4):1500\u20131517. https:\/\/doi.org\/10.7150\/thno.66142","journal-title":"Theranostics"},{"issue":"3","key":"2708_CR8","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1161\/CIRCRESAHA.120.318149","volume":"129","author":"JL Huo","year":"2021","unstructured":"Huo JL, Jiao L, An Q, Chen X, Zhao L, Guo Y, Chen G (2021) Myofibroblast deficiency of LSD1 alleviates TAC-induced heart failure. Circul Res 129(3):400\u2013413. https:\/\/doi.org\/10.1161\/CIRCRESAHA.120.318149","journal-title":"Circul Res"},{"issue":"1","key":"2708_CR9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12943-022-01557-1","volume":"21","author":"DD Shen","year":"2022","unstructured":"Shen DD, Pang JR, Bi YP, Zhang L, Liu Y, Zhao C, Xu H (2022) LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer. Mol Cancer 21(1):75. https:\/\/doi.org\/10.1186\/s12943-022-01557-1","journal-title":"Mol Cancer"},{"issue":"1","key":"2708_CR10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/ng.268","volume":"41","author":"J Wang","year":"2009","unstructured":"Wang J, Hevi S, Kurash JK, Lei H, Gay F, Bajko J, Pradhan S (2009) The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation. Nat Genet 41(1):125\u2013129. https:\/\/doi.org\/10.1038\/ng.268","journal-title":"Nat Genet"},{"issue":"3","key":"2708_CR11","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.cell.2018.05.052","volume":"174","author":"W Sheng","year":"2018","unstructured":"Sheng W, LaFleur MW, Nguyen TH, Chen S, Chakravarthy A, Conway JR, Shi Y (2018) LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade. Cell 174(3):549\u2013563e19. https:\/\/doi.org\/10.1016\/j.cell.2018.05.052","journal-title":"Cell"},{"issue":"1","key":"2708_CR12","doi-asserted-by":"publisher","first-page":"6831","DOI":"10.1038\/s41467-021-27179-7","volume":"12","author":"Y Liu","year":"2021","unstructured":"Liu Y, Sun Z, Xu Z, Chen M, Shao L, Zhang H, Lu J (2021) LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade. Nat Commun 12(1):6831. https:\/\/doi.org\/10.1038\/s41467-021-27179-7","journal-title":"Nat Commun"},{"issue":"11","key":"2708_CR13","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","volume":"11","author":"Y Ishida","year":"1992","unstructured":"Ishida Y, Agata Y, Shibahara K, Honjo T (1992) Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11(11):3887\u20133895. https:\/\/doi.org\/10.1002\/j.1460-2075.1992.tb05481.x","journal-title":"EMBO J"},{"issue":"8","key":"2708_CR14","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711\u2013723. https:\/\/doi.org\/10.1056\/NEJMoa1003466","journal-title":"N Engl J Med"},{"issue":"19","key":"2708_CR15","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1073\/pnas.192461099","volume":"99","author":"Y Iwai","year":"2002","unstructured":"Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99(19):12293\u201312297. https:\/\/doi.org\/10.1073\/pnas.192461099","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"2708_CR16","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00262-004-0593-x","volume":"54","author":"C Blank","year":"2005","unstructured":"Blank C, Gajewski TF, Mackensen A (2005) Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: Implications for tumor immunotherapy. Cancer Immunol Immunother 54(4):307\u2013314. https:\/\/doi.org\/10.1007\/s00262-004-0593-x","journal-title":"Cancer Immunol Immunother"},{"issue":"26","key":"2708_CR17","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Pardoll DM (2012) Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer. N Engl J Med 366(26):2443\u20132454. https:\/\/doi.org\/10.1056\/NEJMoa1200690","journal-title":"N Engl J Med"},{"issue":"2","key":"2708_CR18","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","volume":"35","author":"TN Gide","year":"2019","unstructured":"Gide TN, Quek C, Menzies AM, Tasker AT, Shang P, Holst J, Long GV (2019) Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1\/anti-CTLA-4 combined therapy. Cancer Cell 35(2):238\u2013255e6. https:\/\/doi.org\/10.1016\/j.ccell.2019.01.003","journal-title":"Cancer Cell"},{"issue":"7866","key":"2708_CR19","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41586-021-03520-4","volume":"595","author":"GK Griffin","year":"2021","unstructured":"Griffin GK, Wu J, Iracheta-Vellve A, Patti JC, Hsu J, Davis T, Regev A (2021) Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity. Nature 595(7866):309\u2013314. https:\/\/doi.org\/10.1038\/s41586-021-03520-4","journal-title":"Nature"},{"issue":"6","key":"2708_CR20","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.immuni.2016.06.001","volume":"44","author":"JM Pitt","year":"2016","unstructured":"Pitt JM, V\u00e9tizou M, Daill\u00e8re R, Roberti MP, Yamazaki T, Routy B, Kroemer G (2016) Resistance mechanisms to immune-checkpoint blockade in cancer: Tumor-intrinsic and -extrinsic factors. Immunity 44(6):1255\u20131269. https:\/\/doi.org\/10.1016\/j.immuni.2016.06.001","journal-title":"Immunity"},{"issue":"5","key":"2708_CR21","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.apsb.2019.09.006","volume":"10","author":"X Chen","year":"2020","unstructured":"Chen X, Pan X, Zhang W, Guo H, Cheng S, He Q, Chen L (2020) Epigenetic strategies synergize with PD-L1\/PD-1 targeted cancer immunotherapies to enhance antitumor responses. Acta Pharm Sinica B 10(5):723\u2013733. https:\/\/doi.org\/10.1016\/j.apsb.2019.09.006","journal-title":"Acta Pharm Sinica B"},{"issue":"11","key":"2708_CR22","doi-asserted-by":"publisher","first-page":"e012138","DOI":"10.1136\/jitc-2025-012138","volume":"13","author":"S Russo","year":"2025","unstructured":"Russo S, Giannoula Y, Feola S, Cerioni J, Hamdan F, Chiaro J, Cerullo V (2025) Effect of extracellular vesicles in remodeling the tumor microenvironment by DNMT1 downregulation for enhanced cancer immunotherapy. J Immunother Cancer 13(11):e012138. https:\/\/doi.org\/10.1136\/jitc-2025-012138","journal-title":"J Immunother Cancer"},{"issue":"5","key":"2708_CR23","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1158\/2326-6066.CIR-22-0317","volume":"11","author":"L Li","year":"2023","unstructured":"Li L, Hao S, Gao M, Liu J, Xu X, Huang J, Yang H (2023) HDAC3 inhibition promotes antitumor immunity by enhancing CXCL10-mediated chemotaxis and recruiting of immune cells. Cancer Immunol Res 11(5):657\u2013673. https:\/\/doi.org\/10.1158\/2326-6066.CIR-22-0317","journal-title":"Cancer Immunol Res"},{"key":"2708_CR24","doi-asserted-by":"publisher","first-page":"10501","DOI":"10.1038\/ncomms10501","volume":"7","author":"S Koyama","year":"2016","unstructured":"Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Freeman GJ (2016) Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun 7:10501. https:\/\/doi.org\/10.1038\/ncomms10501","journal-title":"Nat Commun"},{"issue":"1","key":"2708_CR25","doi-asserted-by":"publisher","first-page":"5627","DOI":"10.1038\/s41467-020-19474-5","volume":"11","author":"D Morel","year":"2020","unstructured":"Morel D, Jeffery D, Aspeslagh S, Almouzni G, Postel-Vinay S (2020) EZH2 inhibition activates immune signalling in triple-negative breast cancer. Nat Commun 11(1):5627. https:\/\/doi.org\/10.1038\/s41467-020-19474-5","journal-title":"Nat Commun"},{"issue":"2","key":"2708_CR26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41590-020-00834-9","volume":"22","author":"NE Scharping","year":"2021","unstructured":"Scharping NE, Rivadeneira DB, Menk AV, Vignali PDA, Ford BR, Rittenhouse NL, Delgoffe GM (2021) Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. Nat Immunol 22(2):205\u2013215. https:\/\/doi.org\/10.1038\/s41590-020-00834-9","journal-title":"Nat Immunol"},{"key":"2708_CR27","doi-asserted-by":"publisher","unstructured":"Baretti M, Murphy AG, Zahurak M, Gianino N, Parkinson R, Walker R, Azad NS (2023) A study of using epigenetic modulators to enhance response to pembrolizumab (MK-3475) in microsatellite stable advanced colorectal cancer. Clin Epigenetics 15(1):Article 74. https:\/\/doi.org\/10.1186\/s13148-023-01485-x","DOI":"10.1186\/s13148-023-01485-x"},{"issue":"18","key":"2708_CR28","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.3390\/cancers17182953","volume":"17","author":"FR Riyas Mohamed","year":"2025","unstructured":"Riyas Mohamed FR, Aldubaisi S, Akbar A, Khan MI, Yaqinuddin A (2025) Epigenetic reprogramming by decitabine in triple-negative breast cancer: Mechanisms, immune modulation, and therapeutic synergy. Cancers 17(18):2953. https:\/\/doi.org\/10.3390\/cancers17182953","journal-title":"Cancers"},{"key":"2708_CR29","doi-asserted-by":"publisher","unstructured":"Marrone, K. A., Landon, B., Tsai, H.-L., Topper, M., Hu, C., Nieva, J. J., \u2026 Brahmer,J. R. (2025). P1.11.72 Phase II study of combination azacitidine and entinostat and nivolumab in patients with metastatic non-small cell lung cancer. Journal of Thoracic Oncology, 20(10, Supplement 1), S201. https:\/\/doi.org\/10.1016\/j.jtho.2025.09.372","DOI":"10.1016\/j.jtho.2025.09.372"},{"key":"2708_CR30","doi-asserted-by":"publisher","unstructured":"Chen, Y., Yang, Y., Wang, F., Wan, K., Yamane, K., Zhang, Y., \u2026 Shi, Y. (2006). Crystal structure of human histone lysine-specific demethylase 1 (LSD1). Proceedings of the National Academy of Sciences of the United States of America, 103(38), 13956\u201313961. https:\/\/doi.org\/10.1073\/pnas.0606389103","DOI":"10.1073\/pnas.0606389103"},{"issue":"5","key":"2708_CR31","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.molcel.2020.03.031","volume":"78","author":"SA Kim","year":"2020","unstructured":"Kim SA, Zhu J, Yennawar N, Eek P, Tan S (2020) Crystal structure of the LSD1\/CoREST histone demethylase bound to its nucleosome substrate. Mol Cell 78(5):903\u2013914e4. https:\/\/doi.org\/10.1016\/j.molcel.2020.03.031","journal-title":"Mol Cell"},{"issue":"3","key":"2708_CR32","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.molcel.2006.07.012","volume":"23","author":"M Yang","year":"2006","unstructured":"Yang M, Gocke CB, Luo X, Borek D, Tomchick DR, Machius M, Yu H (2006) Structural basis for CoREST-dependent demethylation of nucleosomes by the human LSD1 histone demethylase. Mol Cell 23(3):377\u2013387. https:\/\/doi.org\/10.1016\/j.molcel.2006.07.012","journal-title":"Mol Cell"},{"issue":"12","key":"2708_CR33","doi-asserted-by":"publisher","first-page":"4756","DOI":"10.1111\/bcp.14912","volume":"87","author":"W Yin","year":"2021","unstructured":"Yin W, Arkilo D, Khudyakov P, M\u00e4kinen PI, Rahkama V, Kosonen H, V\u00e4\u00e4n\u00e4nen HK (2021) Safety, pharmacokinetics and pharmacodynamics of TAK-418, a novel inhibitor of the epigenetic modulator lysine-specific demethylase 1A. Br J Clin Pharmacol 87(12):4756\u20134768. https:\/\/doi.org\/10.1111\/bcp.14912","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"2708_CR34","doi-asserted-by":"publisher","first-page":"E244","DOI":"10.1073\/pnas.1718759114","volume":"115","author":"J Wang","year":"2018","unstructured":"Wang J, Saijo K, Skola D, Jin C, Ma Q, Merkurjev D, Glass CK (2018) Histone demethylase LSD1 regulates hematopoietic stem cell homeostasis and protects from death by endotoxic shock. Proc Natl Acad Sci USA 115(2):E244\u2013E252. https:\/\/doi.org\/10.1073\/pnas.1718759114","journal-title":"Proc Natl Acad Sci USA"},{"key":"2708_CR35","doi-asserted-by":"publisher","unstructured":"Jutzi JS, Kleppe M, Dias J, Staehle HF, Shank K, Teruya-Feldstein J,\u2026 Levine RL (2018) LSD1 inhibition prolongs survival in mouse models of MPN by selectively targeting the disease clone. Hemasphere 2(3):e54. https:\/\/doi.org\/10.1097\/HS9.0000000000000054","DOI":"10.1097\/HS9.0000000000000054"},{"issue":"20","key":"2708_CR36","doi-asserted-by":"publisher","first-page":"4551","DOI":"10.1158\/1078-0432.CCR-22-1128","volume":"28","author":"JB Hiatt","year":"2022","unstructured":"Hiatt JB, Sandborg H, Garrison SM, Cobb S, Baldwin D, Hashizume R, Sage J (2022) Inhibition of LSD1 with Bomedemstat sensitizes small cell lung cancer to immune checkpoint blockade and T-cell killing. Clin Cancer Res 28(20):4551\u20134564. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1128","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2708_CR37","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1021\/acschemneuro.1c00713","volume":"13","author":"R Baba","year":"2022","unstructured":"Baba R, Matsuda S, Maeda R, Taniguchi Y, Yamada K, Okada M, Hattori Y (2022) Investigating the therapeutic potential of LSD1 enzyme activity-specific inhibition by TAK-418 for social and memory deficits in rodent disease models. ACS Chem Neurosci 13(3):313\u2013321. https:\/\/doi.org\/10.1021\/acschemneuro.1c00713","journal-title":"ACS Chem Neurosci"},{"issue":"7","key":"2708_CR38","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1021\/acs.jmedchem.0c01937","volume":"64","author":"Y Hattori","year":"2021","unstructured":"Hattori Y, Matsuda S, Baba R, Okada M, Maeda R, Yamada K, Tohyama K (2021) Design, synthesis, and evaluation of (2-aminocyclopropyl) phenyl derivatives as novel positron emission tomography imaging agents for lysine-specific demethylase 1 in the brain. J Med Chem 64(7):3780\u20133793. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c01937","journal-title":"J Med Chem"},{"key":"2708_CR39","doi-asserted-by":"publisher","unstructured":"Lv T, Yuan D, Miao X, Lv Y, Zhan P, Shen X, \u2026 Song Y (2012) Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer.PLoS ONE 7(4):e35065. https:\/\/doi.org\/10.1371\/journal.pone.0035065","DOI":"10.1371\/journal.pone.0035065"},{"issue":"4","key":"2708_CR40","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/nm.2661","volume":"18","author":"T Schenk","year":"2012","unstructured":"Schenk T, Chen WC, G\u00f6llner S, Howell L, Jin L, Hebestreit K, Brown J (2012) Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med 18(4):605\u2013611. https:\/\/doi.org\/10.1038\/nm.2661","journal-title":"Nat Med"},{"key":"2708_CR41","doi-asserted-by":"publisher","first-page":"113254","DOI":"10.1016\/j.ejmech.2021.113254","volume":"214","author":"DJ Fu","year":"2021","unstructured":"Fu DJ, Li J, Yu B (2021) Annual review of LSD1\/KDM1A inhibitors in 2020. Eur J Med Chem 214:113254. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113254","journal-title":"Eur J Med Chem"},{"issue":"11","key":"2708_CR42","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41551-021-00805-x","volume":"5","author":"Z Van der Zhou","year":"2021","unstructured":"Zhou Z, Van der Jeught K, Fang Y, Yu T, Li Y, Ao Z, Lu X (2021) An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity. Nat Biomedical Eng 5(11):1320\u20131335. https:\/\/doi.org\/10.1038\/s41551-021-00805-x","journal-title":"Nat Biomedical Eng"},{"issue":"5","key":"2708_CR43","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","volume":"162","author":"KB Chiappinelli","year":"2015","unstructured":"Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, Baylin SB (2015) Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 162(5):974\u2013986. https:\/\/doi.org\/10.1016\/j.cell.2015.07.011","journal-title":"Cell"},{"issue":"5","key":"2708_CR44","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.3390\/jcm10051112","volume":"10","author":"H Kim","year":"2021","unstructured":"Kim H, Son BK, Kwon M, Kim D-H, Min K-W (2021) High KDM1A expression associated with decreased CD8\u2009+\u2009T cells reduces the breast cancer survival rate in patients with breast cancer. J Clin Med 10(5):1112. https:\/\/doi.org\/10.3390\/jcm10051112","journal-title":"J Clin Med"},{"key":"2708_CR45","doi-asserted-by":"publisher","unstructured":"Zhang J, Zhu J, Zheng G, Wang Q, Li X, Feng Y, \u2026 Wang J (2022) Co-expression of miR155 or LSD1 shRNA increases the anti-tumor functions of CD19 CAR-T cells. Frontiers in Immunology 12:811364. https:\/\/doi.org\/10.3389\/fimmu.2021.811364","DOI":"10.3389\/fimmu.2021.811364"},{"key":"2708_CR46","doi-asserted-by":"publisher","unstructured":"Kerenyi MA, Shao Z, Hsu YJ, Guo G, Luc S, O\u2019Brien K, \u2026 Orkin SH (2013) Histone demethylase Lsd1 represses hematopoietic stem and progenitor cell signatures during blood cell maturation. eLife. 2013;2:e00633. https:\/\/doi.org\/10.7554\/eLife.00633","DOI":"10.7554\/eLife.00633"},{"issue":"4","key":"2708_CR47","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1158\/0008-5472.CAN-17-1224","volume":"78","author":"C Liu","year":"2018","unstructured":"Liu C, Liu L, Chen X, Shen J, Shan J, Xu Y, Wang H (2018) LSD1 stimulates cancer-associated fibroblasts to drive Notch3-dependent self-renewal of liver cancer stem-like cells. Cancer Res 78(4):938\u2013949. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-1224","journal-title":"Cancer Res"},{"issue":"6","key":"2708_CR48","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.cell.2010.08.030","volume":"142","author":"K Rai","year":"2010","unstructured":"Rai K, Sarkar S, Broadbent TJ, Voas M, Grossmann KF, Nadauld LD, Jones DA (2010) DNA demethylase activity maintains intestinal cells in an undifferentiated state following loss of APC. Cell 142(6):930\u2013942. https:\/\/doi.org\/10.1016\/j.cell.2010.08.030","journal-title":"Cell"},{"key":"2708_CR49","doi-asserted-by":"publisher","first-page":"117114","DOI":"10.1016\/j.lfs.2019.117114","volume":"241","author":"HS Zhang","year":"2020","unstructured":"Zhang HS, Liu HY, Zhou Z, Sun HL, Liu MY (2020) TSPAN8 promotes colorectal cancer cell growth and migration in LSD1-dependent manner. Life Sci 241:117114. https:\/\/doi.org\/10.1016\/j.lfs.2019.117114","journal-title":"Life Sci"},{"key":"2708_CR50","doi-asserted-by":"publisher","unstructured":"Antona A, Leo G, Favero F, Giani F, Fasano C, Di Carlo S, \u2026 Benelli M (2023) Targeting lysine-specific demethylase 1 (KDM1A\/LSD1) impairs colorectal cancer tumorigenesis by affecting cancer cells stemness, motility, and differentiation. Cell Death Discovery 9(1):201. https:\/\/doi.org\/10.1038\/s41420-023-01502-1","DOI":"10.1038\/s41420-023-01502-1"},{"issue":"4","key":"2708_CR51","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","volume":"12","author":"WH Fridman","year":"2012","unstructured":"Fridman WH, Pag\u00e8s F, Saut\u00e8s-Fridman C, Galon J (2012) The immune contexture in human tumours: Impact on clinical outcome. Nat Rev Cancer 12(4):298\u2013306. https:\/\/doi.org\/10.1038\/nrc3245","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"2708_CR52","doi-asserted-by":"publisher","first-page":"a006676","DOI":"10.1101\/cshperspect.a006676","volume":"2","author":"RS Watnick","year":"2012","unstructured":"Watnick RS (2012) The role of the tumor microenvironment in regulating angiogenesis. Cold Spring Harbor Perspect Med 2(12):a006676. https:\/\/doi.org\/10.1101\/cshperspect.a006676","journal-title":"Cold Spring Harbor Perspect Med"},{"key":"2708_CR53","doi-asserted-by":"publisher","unstructured":"Xia L, Oyang L, Lin J, Tan S, Han Y, Wu N, \u2026 Tang Y (2021) The cancer metabolic reprogramming and immune response. Molecular Cancer 20(1):28. https:\/\/doi.org\/10.1186\/s12943-021-01305-2","DOI":"10.1186\/s12943-021-01305-2"},{"key":"2708_CR54","doi-asserted-by":"publisher","first-page":"107753","DOI":"10.1016\/j.pharmthera.2021.107753","volume":"221","author":"Y Xiao","year":"2021","unstructured":"Xiao Y, Yu D (2021) Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther 221:107753. https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107753","journal-title":"Pharmacol Ther"},{"issue":"5","key":"2708_CR55","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Krummel MF (2018) Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 24(5):541\u2013550. https:\/\/doi.org\/10.1038\/s41591-018-0014-x","journal-title":"Nat Med"},{"issue":"9","key":"2708_CR56","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1152\/physiolgenomics.00195.2024","volume":"57","author":"J Jiang","year":"2025","unstructured":"Jiang J, Luo S, Chen X, Liu D, Zheng P, Kong F, Li L (2025) Transcriptional activation of FGL1 by KDM1A promotes immune evasion in lung cancer. Physiol Genom 57(9):518\u2013525. https:\/\/doi.org\/10.1152\/physiolgenomics.00195.2024","journal-title":"Physiol Genom"},{"key":"2708_CR57","doi-asserted-by":"publisher","unstructured":"Qiu F, Jiang P, Zhang G, Li H, Wang J, Liu Y, \u2026 Zhou Z (2024) Priming with LSD1 inhibitors promotes the persistence and antitumor effect of adoptively transferred T cells. Nature Communications 15(1):4327. https:\/\/doi.org\/10.1038\/s41467-024-48607-4","DOI":"10.1038\/s41467-024-48607-4"},{"issue":"11","key":"2708_CR58","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/s41419-021-04297-0","volume":"12","author":"Y Han","year":"2021","unstructured":"Han Y, Xu S, Ye W, Zhang H, Liu Y, Li Z, Sun W (2021) Targeting LSD1 suppresses stem cell-like properties and sensitizes head and neck squamous cell carcinoma to PD-1 blockade. Cell Death Dis 12(11):993. https:\/\/doi.org\/10.1038\/s41419-021-04297-0","journal-title":"Cell Death Dis"},{"issue":"1","key":"2708_CR59","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41590-018-0273-1","volume":"20","author":"K Hatzi","year":"2019","unstructured":"Hatzi K, Geng H, Doane AS, Meydan C, LaRiviere R, Cardenas M, Melnick A (2019) Histone demethylase LSD1 is required for germinal center formation and BCL6-driven lymphomagenesis. Nat Immunol 20(1):86\u201396. https:\/\/doi.org\/10.1038\/s41590-018-0273-1","journal-title":"Nat Immunol"},{"issue":"10","key":"2708_CR60","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1158\/0008-5472.CAN-10-4316","volume":"71","author":"PB Olkhanud","year":"2011","unstructured":"Olkhanud PB, Damdinsuren B, Bodogai M, Gress RE, Sen R, Wejksza K, Biragyn A (2011) Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4\u207a T cells to T-regulatory cells. Cancer Res 71(10):3505\u20133515. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-4316","journal-title":"Cancer Res"},{"issue":"4","key":"2708_CR61","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.immuni.2013.10.003","volume":"39","author":"G Bindea","year":"2013","unstructured":"Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Galon J (2013) Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39(4):782\u2013795. https:\/\/doi.org\/10.1016\/j.immuni.2013.10.003","journal-title":"Immunity"},{"issue":"12","key":"2708_CR62","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1016\/j.immuni.2021.10.014","volume":"54","author":"AE Overacre-Delgoffe","year":"2021","unstructured":"Overacre-Delgoffe AE, Bumgarner HJ, Cillo AR, Burr AHP, Tometich JT, Shan Q, Delgoffe GM (2021) Microbiota-specific T follicular helper cells drive tertiary lymphoid structures and anti-tumor immunity against colorectal cancer. Immunity 54(12):2812\u20132824e4. https:\/\/doi.org\/10.1016\/j.immuni.2021.10.014","journal-title":"Immunity"},{"issue":"6","key":"2708_CR63","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1002\/art.42091","volume":"74","author":"K Doi","year":"2022","unstructured":"Doi K, Murata K, Ito S, Nakagawa T, Yamamoto K, Nakamura T (2022) Role of lysine-specific demethylase 1 in metabolically integrating osteoclast differentiation and inflammatory bone resorption through hypoxia-inducible factor 1\u03b1 and E2F1. Arthritis Rheumatol 74(6):948\u2013960. https:\/\/doi.org\/10.1002\/art.42091","journal-title":"Arthritis Rheumatol"},{"key":"2708_CR64","doi-asserted-by":"publisher","unstructured":"Fu J, Han Z, Wu Z, Chen Y, Lu J, Zhang Y, \u2026 Li L (2022) GABA regulates IL-1\u03b2 production in macrophages. Cell Reports 41(10):111770. https:\/\/doi.org\/10.1016\/j.celrep.2022.111770","DOI":"10.1016\/j.celrep.2022.111770"},{"issue":"3","key":"2708_CR65","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1093\/nar\/gkac1230","volume":"51","author":"Z Huang","year":"2023","unstructured":"Huang Z, Efthymiadou A, Liang N, Fan R, Treuter E (2023) Antagonistic action of GPS2 and KDM1A at enhancers governs alternative macrophage activation by interleukin 4. Nucleic Acids Res 51(3):1067\u20131086. https:\/\/doi.org\/10.1093\/nar\/gkac1230","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"2708_CR66","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1093\/neuonc\/noaa058","volume":"22","author":"CP Bailey","year":"2020","unstructured":"Bailey CP, Figueroa M, Gangadharan A, Teng M, Sano M, Han H, Hashizume R (2020) Pharmacologic inhibition of lysine-specific demethylase 1 as a therapeutic and immune-sensitization strategy in pediatric high-grade glioma. Neurooncology 22(9):1302\u20131314. https:\/\/doi.org\/10.1093\/neuonc\/noaa058","journal-title":"Neurooncology"},{"issue":"1","key":"2708_CR67","doi-asserted-by":"publisher","first-page":"2016158","DOI":"10.1080\/2162402X.2021.2016158","volume":"11","author":"M Liu","year":"2022","unstructured":"Liu M, Du M, Yu J, Guo F, Zhang X, Sun J (2022) CEBPA mutants down-regulate AML cell susceptibility to NK-mediated lysis by disruption of the expression of NKG2D ligands, which can be restored by LSD1 inhibition. OncoImmunology 11(1):2016158. https:\/\/doi.org\/10.1080\/2162402X.2021.2016158","journal-title":"OncoImmunology"},{"issue":"11","key":"2708_CR68","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/s43018-021-00269-7","volume":"2","author":"AR Parikh","year":"2021","unstructured":"Parikh AR, Szabolcs A, Allen JN, Clark JW, Wo JY, Raabe M, Meyerhardt JA (2021) Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. Nat Cancer 2(11):1124\u20131135. https:\/\/doi.org\/10.1038\/s43018-021-00269-7","journal-title":"Nat Cancer"},{"key":"2708_CR69","doi-asserted-by":"publisher","unstructured":"Hong X, Huang H, Qiu X, Ding Z, Feng X, Zhang H, \u2026 Song J (2018) Targeting posttranslational modifications of RIOK1 inhibits the progression of colorectal and gastric cancers. eLife. 2018;7:e29511. https:\/\/doi.org\/10.7554\/eLife.29511","DOI":"10.7554\/eLife.29511"},{"issue":"4","key":"2708_CR70","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/bjc.2013.387","volume":"109","author":"J Ding","year":"2013","unstructured":"Ding J, Zhang ZM, Xia Y, Liao G, Pan Y, Liu S, Wang C (2013) LSD1-mediated epigenetic modification contributes to proliferation and metastasis of colon cancer. Br J Cancer 109(4):994\u20131003. https:\/\/doi.org\/10.1038\/bjc.2013.387","journal-title":"Br J Cancer"},{"issue":"2","key":"2708_CR71","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.celrep.2014.06.016","volume":"8","author":"Y Lu","year":"2014","unstructured":"Lu Y, Wajapeyee N, Turker MS, Glazer PM (2014) Silencing of the DNA mismatch repair gene MLH1 induced by hypoxic stress in a pathway dependent on the histone demethylase LSD1. Cell Rep 8(2):501\u2013513. https:\/\/doi.org\/10.1016\/j.celrep.2014.06.016","journal-title":"Cell Rep"},{"issue":"7","key":"2708_CR72","doi-asserted-by":"publisher","first-page":"e70077","DOI":"10.1371\/journal.pone.0070077","volume":"8","author":"Z Huang","year":"2013","unstructured":"Huang Z, Li S, Song W, Li X, Li Q, Zhang Z (2013) Lysine-specific demethylase 1 (LSD1\/KDM1A) contributes to colorectal tumorigenesis via activation of the Wnt\/\u03b2-catenin pathway by down-regulating Dickkopf-1 (DKK1). PLoS ONE 8(7):e70077. https:\/\/doi.org\/10.1371\/journal.pone.0070077","journal-title":"PLoS ONE"},{"key":"2708_CR73","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12935-020-01203-3","volume":"20","author":"Z Yang","year":"2020","unstructured":"Yang Z, Zhang C, Feng Y, Quan M, Cui Y, Xuan Y (2020) Tenascin-C predicts poor outcomes for patients with colorectal cancer and drives cancer stemness via Hedgehog signaling pathway. Cancer Cell Int 20:122. https:\/\/doi.org\/10.1186\/s12935-020-01203-3","journal-title":"Cancer Cell Int"},{"key":"2708_CR74","doi-asserted-by":"publisher","unstructured":"Lian Y, Xu Y, Xiao C, Xia R, Gong H, Yang P, \u2026 Liu X (2017) The pseudogene derived from long non-coding RNA DUXAP10 promotes colorectal cancer cell growth through epigenetically silencing of p21 and PTEN. Scientific Reports 7(1):7312. https:\/\/doi.org\/10.1038\/s41598-017-07853-9","DOI":"10.1038\/s41598-017-07853-9"},{"issue":"5","key":"2708_CR75","first-page":"1830","volume":"24","author":"A Gong","year":"2019","unstructured":"Gong A, Huang Z, Ge H, Cai Y, Yang C (2019) The carcinogenic complex lncRNA DUXAP8\/EZH2\/LSD1 accelerates the proliferation, migration and invasion of colorectal cancer. J BUON 24(5):1830\u20131836 PMID:31880069","journal-title":"J BUON"},{"issue":"7","key":"2708_CR76","doi-asserted-by":"publisher","first-page":"e9230","DOI":"10.1590\/1414-431X20209230","volume":"53","author":"J Chen","year":"2020","unstructured":"Chen J, Zhao J, Ding J, Wang Z, Du J, Wu C (2020) Knocking down LSD1 inhibits the stemness features of colorectal cancer stem cells. Braz J Med Biol Res 53(7):e9230. https:\/\/doi.org\/10.1590\/1414-431X20209230","journal-title":"Braz J Med Biol Res"},{"issue":"2","key":"2708_CR77","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/1541-7786.MCR-19-0748","volume":"18","author":"SA Miller","year":"2020","unstructured":"Miller SA, Policastro RA, Savant SS et al (2020) Lysine-specific demethylase 1 mediates AKT activity and promotes epithelial-to-mesenchymal transition in PIK3CA-mutant colorectal cancer. Mol Cancer Res 18(2):264\u2013277. https:\/\/doi.org\/10.1158\/1541-7786.MCR-19-0748","journal-title":"Mol Cancer Res"},{"issue":"3","key":"2708_CR78","doi-asserted-by":"publisher","first-page":"e006245","DOI":"10.1136\/jitc-2022-006245","volume":"11","author":"X Wang","year":"2023","unstructured":"Wang X, Li Y, Chen H, Zhang L, Wang J, Zhang Y (2023) Targeting LSD1 suppresses stem cell-like properties and enhances anti-PD-1 therapy in colorectal cancer. J Immunother Cancer 11(3):e006245. https:\/\/doi.org\/10.1136\/jitc-2022-006245","journal-title":"J Immunother Cancer"},{"issue":"24","key":"2708_CR79","doi-asserted-by":"publisher","first-page":"13670","DOI":"10.1073\/pnas.1918307117","volume":"117","author":"TP Braun","year":"2020","unstructured":"Braun TP, Coblentz C, Curtiss BM et al (2020) Combined inhibition of JAK\/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R\/CEBPA mutant acute myeloid leukemia. Proc Natl Acad Sci USA 117(24):13670\u201313679. https:\/\/doi.org\/10.1073\/pnas.1918307117","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"2708_CR80","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1158\/2159-8290.CD-20-1741","volume":"11","author":"X Zhou","year":"2021","unstructured":"Zhou X, Singh M, Sanz Santos G et al (2021) Pharmacologic activation of p53 triggers viral mimicry response thereby abolishing tumor immune evasion and promoting antitumor immunity. Cancer Discov 11(12):3090\u20133105. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1741","journal-title":"Cancer Discov"},{"issue":"4","key":"2708_CR81","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.tibs.2008.01.002","volume":"33","author":"F Forneris","year":"2008","unstructured":"Forneris F, Binda C, Battaglioli E, Mattevi A (2008) LSD1: Oxidative chemistry for multifaceted functions in chromatin regulation. Trends Biochem Sci 33(4):181\u2013189. https:\/\/doi.org\/10.1016\/j.tibs.2008.01.002","journal-title":"Trends Biochem Sci"},{"issue":"27","key":"2708_CR82","doi-asserted-by":"publisher","first-page":"8058","DOI":"10.1021\/bi700664y","volume":"46","author":"M Yang","year":"2007","unstructured":"Yang M, Culhane JC, Szewczuk LM et al (2007) Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine. Biochemistry 46(27):8058\u20138065. https:\/\/doi.org\/10.1021\/bi700664y","journal-title":"Biochemistry"},{"issue":"4","key":"2708_CR83","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/s41416-019-0680-6","volume":"122","author":"W Zhang","year":"2020","unstructured":"Zhang W, Cheng J, Diao P et al (2020) Therapeutically targeting head and neck squamous cell carcinoma through synergistic inhibition of LSD1 and JMJD3 by TCP and GSK-J1. Br J Cancer 122(4):528\u2013538. https:\/\/doi.org\/10.1038\/s41416-019-0680-6","journal-title":"Br J Cancer"},{"issue":"7","key":"2708_CR84","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1158\/1078-0432.CCR-20-4054","volume":"27","author":"MM Tayari","year":"2021","unstructured":"Tayari MM, Santos HGD, Kwon D et al (2021) Clinical responsiveness to all-trans retinoic acid is potentiated by LSD1 inhibition and associated with a quiescent transcriptome in myeloid malignancies. Clin Cancer Res 27(7):1893\u20131903. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4054","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2708_CR85","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1080\/10428194.2019.1709944","volume":"61","author":"AA Lane","year":"2020","unstructured":"Lane AA, Chrysofakis G, Doherty L et al (2020) A phase I study of the combination of the LSD1 inhibitor tranylcypromine and all-trans retinoic acid in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome. Leuk Lymphoma 61(5):1231\u20131241. https:\/\/doi.org\/10.1080\/10428194.2019.1709944","journal-title":"Leuk Lymphoma"},{"issue":"36","key":"2708_CR86","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1200\/JCO.19.03250","volume":"38","author":"O Salamero","year":"2020","unstructured":"Salamero O, Montesinos P, Willekens C et al (2020) First-in-human phase I study of iadademstat (ORY-1001): A first-in-class lysine-specific histone demethylase 1A inhibitor, in relapsed or refractory acute myeloid leukemia. J Clin Oncol 38(36):4260\u20134273. https:\/\/doi.org\/10.1200\/JCO.19.03250","journal-title":"J Clin Oncol"},{"issue":"3","key":"2708_CR87","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.ccell.2018.02.002","volume":"33","author":"T Maes","year":"2018","unstructured":"Maes T, Mascar\u00f3 C, Tirapu I et al (2018) ORY-1001, a potent and selective covalent KDM1A inhibitor, for the treatment of acute leukemia. Cancer Cell 33(3):495\u2013511e12. https:\/\/doi.org\/10.1016\/j.ccell.2018.02.002","journal-title":"Cancer Cell"},{"key":"2708_CR88","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.3389\/fphar.2018.01411","volume":"9","author":"Z Lu","year":"2018","unstructured":"Lu Z, Guo Y, Zhang X et al (2018) ORY-1001 suppresses cell growth and induces apoptosis in lung cancer through triggering HK2-mediated Warburg effect. Front Pharmacol 9:1411. https:\/\/doi.org\/10.3389\/fphar.2018.01411","journal-title":"Front Pharmacol"},{"issue":"22","key":"2708_CR89","doi-asserted-by":"publisher","first-page":"4060","DOI":"10.1182\/blood.V128.22.4060.4060","volume":"128","author":"T Somervaille","year":"2016","unstructured":"Somervaille T, Salamero O, Montesinos P, Willekens C, Perez Simon JA, Pigneux A, Bosch F (2016) Safety, pharmacokinetics (PK), pharmacodynamics (PD)and preliminary activity in acute leukemia of Ory-1001, a first-in-class inhibitor of lysine-specific histone demethylase 1A (LSD1\/KDM1A): Initial results from a first-in-human phase 1 study. Blood 128(22):4060. https:\/\/doi.org\/10.1182\/blood.V128.22.4060.4060","journal-title":"Blood"},{"issue":"5","key":"2708_CR90","doi-asserted-by":"publisher","first-page":"e0233468","DOI":"10.1371\/journal.pone.0233468","volume":"15","author":"T Maes","year":"2020","unstructured":"Maes T, Mascar\u00f3 C, Rotllant D et al (2020) Modulation of KDM1A with vafidemstat rescues memory deficit and behavioral alterations. PLoS ONE 15(5):e0233468. https:\/\/doi.org\/10.1371\/journal.pone.0233468","journal-title":"PLoS ONE"},{"issue":"6","key":"2708_CR91","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.3324\/haematol.2018.199190","volume":"104","author":"KN Smitheman","year":"2019","unstructured":"Smitheman KN, Severson TM, Rajapurkar SR et al (2019) Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-trans retinoic acid in acute myeloid leukemia across subtypes. Haematologica 104(6):1156\u20131167. https:\/\/doi.org\/10.3324\/haematol.2018.199190","journal-title":"Haematologica"},{"key":"2708_CR92","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.3389\/fonc.2020.01234","volume":"10","author":"Q Xie","year":"2020","unstructured":"Xie Q, Tang T, Pang J et al (2020) LSD1 promotes bladder cancer progression by upregulating LEF1 and enhancing EMT. Front Oncol 10:1234. https:\/\/doi.org\/10.3389\/fonc.2020.01234","journal-title":"Front Oncol"},{"issue":"12","key":"2708_CR93","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1038\/s41375-022-01716-9","volume":"36","author":"A Benyoucef","year":"2022","unstructured":"Benyoucef A, Haigh K, Cuddihy A, Haigh JJ (2022) JAK\/BCL2 inhibition acts synergistically with LSD1 inhibitors to selectively target ETP-ALL. Leukemia 36(12):2802\u20132816. https:\/\/doi.org\/10.1038\/s41375-022-01716-9","journal-title":"Leukemia"},{"issue":"10","key":"2708_CR94","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1016\/j.jtho.2019.06.021","volume":"14","author":"TM Bauer","year":"2019","unstructured":"Bauer TM, Besse B, Martinez-Marti A et al (2019) Phase I, open-label, dose-escalation study of the safety, pharmacokinetics, pharmacodynamics, and efficacy of GSK2879552 in relapsed\/refractory SCLC. J Thorac Oncol 14(10):1828\u20131838. https:\/\/doi.org\/10.1016\/j.jtho.2019.06.021","journal-title":"J Thorac Oncol"},{"issue":"2","key":"2708_CR95","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1080\/10428194.2021.2012667","volume":"63","author":"GJ Roboz","year":"2022","unstructured":"Roboz GJ, Yee K, Verma A et al (2022) Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed\/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes. Leuk Lymphoma 63(2):463\u2013467. https:\/\/doi.org\/10.1080\/10428194.2021.2012667","journal-title":"Leuk Lymphoma"},{"key":"2708_CR96","doi-asserted-by":"publisher","first-page":"144758","DOI":"10.1016\/j.gene.2020.144758","volume":"752","author":"G Johnston","year":"2020","unstructured":"Johnston G, Ramsey HE, Liu Q et al (2020) Nascent transcript and single-cell RNA-seq analysis defines the mechanism of action of the LSD1 inhibitor INCB059872 in myeloid leukemia. Gene 752:144758. https:\/\/doi.org\/10.1016\/j.gene.2020.144758","journal-title":"Gene"},{"key":"2708_CR97","doi-asserted-by":"publisher","first-page":"114522","DOI":"10.1016\/j.ejmech.2022.114522","volume":"239","author":"Y Hattori","year":"2022","unstructured":"Hattori Y, Matsumoto S, Morimoto S et al (2022) Design, synthesis, and structure\u2013activity relationship of TAK-418 and its derivatives as a novel series of LSD1 inhibitors with lowered risk of hematological side effects. Eur J Med Chem 239:114522. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114522","journal-title":"Eur J Med Chem"},{"issue":"11","key":"2708_CR98","doi-asserted-by":"publisher","first-page":"eaba1187","DOI":"10.1126\/sciadv.aba1187","volume":"7","author":"R Baba","year":"2021","unstructured":"Baba R, Matsuda S, Arakawa Y et al (2021) LSD1 enzyme inhibitor TAK-418 unlocks aberrant epigenetic machinery and improves autism symptoms in neurodevelopmental disorder models. Sci Adv 7(11):eaba1187. https:\/\/doi.org\/10.1126\/sciadv.aba1187","journal-title":"Sci Adv"},{"issue":"17","key":"2708_CR99","doi-asserted-by":"publisher","first-page":"12680","DOI":"10.1021\/acs.jmedchem.1c00653","volume":"64","author":"S Matsuda","year":"2021","unstructured":"Matsuda S, Hattori Y, Matsumiya K et al (2021) Design, synthesis, and evaluation of [18F]T-914 as a novel positron-emission tomography tracer for lysine-specific demethylase 1. J Med Chem 64(17):12680\u201312690. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00653","journal-title":"J Med Chem"},{"issue":"5","key":"2708_CR100","doi-asserted-by":"publisher","first-page":"4335","DOI":"10.1021\/acs.jmedchem.1c02156","volume":"65","author":"C Li","year":"2022","unstructured":"Li C, Su M, Zhu W et al (2022) Structure\u2013activity relationship study of indolin-5-yl-cyclopropanamine derivatives as selective lysine specific demethylase 1 (LSD1) inhibitors. J Med Chem 65(5):4335\u20134349. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c02156","journal-title":"J Med Chem"},{"issue":"2","key":"2708_CR101","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1158\/1078-0432.CCR-20-2380","volume":"27","author":"A Hollebecque","year":"2021","unstructured":"Hollebecque A, Salvagni S, Plummer R et al (2021) Phase I study of lysine-specific demethylase 1 inhibitor, CC-90011, in patients with advanced solid tumors and relapsed\/refractory non-Hodgkin lymphoma. Clin Cancer Res 27(2):438\u2013446. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2380","journal-title":"Clin Cancer Res"},{"issue":"23","key":"2708_CR102","doi-asserted-by":"publisher","first-page":"14522","DOI":"10.1021\/acs.jmedchem.0c00978","volume":"63","author":"T Kanouni","year":"2020","unstructured":"Kanouni T, Severin C, Cho RW et al (2020) Discovery of CC-90011: A potent and selective reversible inhibitor of lysine specific demethylase 1 (LSD1). J Med Chem 63(23):14522\u201314529. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c00978","journal-title":"J Med Chem"},{"key":"2708_CR103","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.3389\/fimmu.2020.02196","volume":"11","author":"CP Bailey","year":"2020","unstructured":"Bailey CP, Figueroa M, Gangadharan A, Lee DA, Chandra J (2020) Scaffolding LSD1 inhibitors impair NK cell metabolism and cytotoxic function through depletion of glutathione. Front Immunol 11:2196. https:\/\/doi.org\/10.3389\/fimmu.2020.02196","journal-title":"Front Immunol"},{"issue":"7","key":"2708_CR104","doi-asserted-by":"publisher","first-page":"e0235705","DOI":"10.1371\/journal.pone.0235705","volume":"15","author":"R Soldi","year":"2020","unstructured":"Soldi R, Ghosh Halder T, Weston A et al (2020) The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch\/Sucrose-NonFermentable (SWI\/SNF) complex mutated ovarian cancer. PLoS ONE 15(7):e0235705. https:\/\/doi.org\/10.1371\/journal.pone.0235705","journal-title":"PLoS ONE"},{"issue":"11","key":"2708_CR105","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1021\/acs.biochem.4c00090","volume":"63","author":"D Senanayaka","year":"2024","unstructured":"Senanayaka D, Zeng D, Deniz E, Priyankara IK, Helmbreck J, Schneider O, Reiter NJ (2024) Anticancer drugs of lysine specific histone demethylase-1(LSD1) display variable inhibition on nucleosome substrates. Biochemistry 63(11):1369\u20131375. https:\/\/doi.org\/10.1021\/acs.biochem.4c00090","journal-title":"Biochemistry"},{"key":"2708_CR106","doi-asserted-by":"publisher","unstructured":"Dhanalakshmi S, Rajagopal S, Sadhu N, Chandru G, Siddiqui A, Wahid S,\u2026 Vishwakarma S (2020) Novel dual inhibitor of LSD1\u2013HDAC6\/8 for treatment of cancer. Blood 136(Supplement 1):29. https:\/\/doi.org\/10.1182\/blood-2020-142685","DOI":"10.1182\/blood-2020-142685"},{"key":"2708_CR107","doi-asserted-by":"publisher","first-page":"104161","DOI":"10.1016\/j.bioorg.2020.104161","volume":"103","author":"G Jia","year":"2020","unstructured":"Jia G, Cang S, Ma P, Song Z (2020) Capsaicin: A hot KDM1A\/LSD1 inhibitor from peppers. Bioorg Chem 103:104161","journal-title":"Bioorg Chem"},{"key":"2708_CR108","doi-asserted-by":"publisher","first-page":"640949","DOI":"10.3389\/fphar.2021.640949","volume":"12","author":"P Ma","year":"2021","unstructured":"Ma P, Jia G, Song Z (2021) Monobenzone, a novel and potent KDM1A inhibitor, suppresses migration of gastric cancer cells. Front Pharmacol 12:640949. https:\/\/doi.org\/10.3389\/fphar.2021.640949","journal-title":"Front Pharmacol"},{"key":"2708_CR109","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.canlet.2019.03.052","volume":"454","author":"Y Li","year":"2019","unstructured":"Li Y, Tao L, Zuo Z et al (2019) ZY0511, a novel, potent and selective LSD1 inhibitor, exhibits anticancer activity against solid tumors via the DDIT4\/mTOR pathway. Cancer Lett 454:179\u2013190. https:\/\/doi.org\/10.1016\/j.canlet.2019.03.052","journal-title":"Cancer Lett"},{"key":"2708_CR110","doi-asserted-by":"publisher","first-page":"175883592093742","DOI":"10.1177\/1758835920937428","volume":"12","author":"W Peng","year":"2020","unstructured":"Peng W, Zhang H, Tan S et al (2020) Synergistic antitumor effect of 5-fluorouracil with the novel LSD1 inhibitor ZY0511 in colorectal cancer. Therapeutic Adv Med Oncol 12:1758835920937428. https:\/\/doi.org\/10.1177\/1758835920937428","journal-title":"Therapeutic Adv Med Oncol"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-026-02708-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00109-026-02708-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-026-02708-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T18:02:01Z","timestamp":1787594521000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00109-026-02708-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":110,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["2708"],"URL":"https:\/\/doi.org\/10.1007\/s00109-026-02708-3","relation":{},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"assertion":[{"value":"30 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This article does not contain any studies with human participants or animals performed by any of the authors.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"101"}}